Health News

Nivolumab Gets Additional Adjuvant Indication for Bladder Cancer

The US Food and Drug Administration has approved nivolumab (Opdivo) for the adjuvant treatment of urothelial carcinoma (UC) in cases in which there is a high risk for recurrence following radical resection, according to an announcement from its maker, Bristol-Meyers Squibb (BMS). The new indication builds on the PD-1 inhibitor’s prior approvals for advanced or […]